Kyverna Therapeutics Reports Q2 2026 Financial Results with Reduced Net Loss

Kyverna Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $38.3 million, a decrease from the $42.1 million loss recorded in the same period of 2025. For the six months ending June 30, 2026, the company reported a net loss of $78.0 million, down from $86.7 million in the prior year. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell by 31% to $24.8 million for the quarter, primarily due to lower costs associated with the company's lead product candidate, mivocabtagene autoleucel (miv-cel). General and administrative expenses, however, increased by 72% to $14.8 million, driven by higher personnel costs and professional services.

As of June 30, 2026, Kyverna's total assets amounted to $219.8 million, a decline from $293.8 million at the end of 2025. The decrease in assets was largely due to a reduction in cash and cash equivalents, which fell to $31.8 million from $124.1 million. The company’s accumulated deficit reached $502.9 million, reflecting its ongoing investment in research and development without generating revenue from product sales. The total liabilities decreased to $54.3 million, down from $61.6 million, primarily due to a reduction in current liabilities.

Kyverna is advancing its clinical programs, particularly focusing on miv-cel for treating stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). The company has received Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA for both indications. In April 2026, Kyverna presented positive results from its Phase 2 clinical trial for SPS, demonstrating significant clinical benefits. The company is currently preparing for a rolling Biologics License Application (BLA) submission, with the Chemistry, Manufacturing, and Controls (CMC) module already submitted in July 2026.

In terms of operational metrics, Kyverna's employee headcount has increased as the company expands its research and development capabilities. The company is also enhancing its commercial infrastructure in anticipation of potential product launches. As of June 30, 2026, Kyverna had cash and cash equivalents, along with available-for-sale marketable securities, totaling $199.4 million, which management believes will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional capital to support ongoing development and commercialization efforts, as it has not yet generated revenue from product sales.

Looking ahead, Kyverna plans to continue its focus on advancing miv-cel through clinical trials and regulatory processes while exploring additional indications for its product candidates. The company remains committed to its long-term strategy of developing innovative therapies for autoimmune diseases, despite the inherent risks and uncertainties associated with drug development.